EUVIMEDEUVIMED entdecken
Crossref

Serum Soluble Fas in Hodgkin′s Disease

AbbasH Abdulsalam, SubuhS Al-Mudalal

Iraqi Journal of Hematology · 2011

DOI: 10.4103/2072-8069.194306 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iraqi Journal of Hematology, 2011. Verfasst von AbbasH Abdulsalam und 1 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Hodgkin disease (HD) is a histologically defined B- cell neoplasm and it includes two distinct types of disease, classical and nodular lymphocyte-predominant Hodgkin's disease. Disruption of the physiological balance between cell proliferation and apoptosis is a universal feature of all cancers. Apoptosis is caused by activation of the caspases through extrinsic and intrinsic pathways. Extrinsic pathway centers on TNF family, where the ligand will bind to the cell surface receptor to induce apoptosis. Fas receptor is a member of the TNF receptor superfamily. Fas family is constituted of the receptor, ligand and soluble form. Soluble Fas will interfere with apoptosis by competing with Fas receptor for binding to legend. The aim of this study is to measure the concentration of serum soluble Fas in Hodgkin's disease patients and to determine the relation between it and certain clinical parameters and serum markers. Also to compare the concentration of serum sFas in HD and Non-Hodgkin's lymphoma (NHL) patients. Patients & Methods: This study included 15 patients with Hodgkin's disease, 9 males and 6 females. The patients were interviewed for history and clinical examination and blood was collected for measurement of serum sFas concentration using ELISA technique. Hemoglobin (Hb) concentration, leucocytes and platelets counts, peripheral blood smear, C-reactive protein (CRP) and lactate dehydrogenase (LDH) level were all performed using standard techniques.

Results

This study revealed that the serum soluble Fas concentration was almost the same (p-value = 0.991) in both HD patients (1996.9 ± 131) and normal controls (1993 ± 125.9). However, by comparing the results of this study with the high concentration results obtained for serum sFas in newly diagnosed NHL patients (6475.9 ± 617) of another study, it revealed a highly significant difference (p-value < 0.0001) between the two groups.

Conclusions

The serum Fas concentration differs significantly between HD and NHL patients but not with control patients. Further studies including larger number of patients are recommended.

Zitieren

APA

Abdulsalam, A., & Al-Mudalal, S. (2011). Serum Soluble Fas in Hodgkin′s Disease. Iraqi Journal of Hematology. https://doi.org/10.4103/2072-8069.194306

Vancouver

Abdulsalam A, Al-Mudalal S. Serum Soluble Fas in Hodgkin′s Disease. Iraqi Journal of Hematology. 2011. doi:10.4103/2072-8069.194306

BibTeX
@article{Abdulsalam2011,
  author = {Abdulsalam, AbbasH and Al-Mudalal, SubuhS},
  title = {Serum Soluble Fas in Hodgkin′s Disease},
  journal = {Iraqi Journal of Hematology},
  year = {2011},
  doi = {10.4103/2072-8069.194306}
}
Kostenlos starten →